1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Aytu BioPharma, Inc.

Aytu BioPharma, Inc.

AYTU
Aytu BioPharma, Inc.US flagNASDAQ Capital Market
2.19
USD
+0.03
- -
17.74MMarket Cap
Aytu BioPharma, Inc.
AYTU
(NASDAQ Capital Market)

Recent

price

2.19

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
218.75
218.75
6,547.67
111.11
18,698.71
55,708.85
15,640.78
1,099.8
187.84
122.29
78.38
65.77
32.16
11.77
10.57
5.66
Revenue per Share
-17,100.25
-7,459.38
-7,164.75
-619,854.44
-6,858.11
-551,671.71
-612,610.52
-109,263.61
-3,061.26
-696.19
-60.28
-69.61
-74.01
-5.11
-2.86
-2.16
-3.41
Basic EPS, GAAP
-8,102.25
-4,731.12
-4,713
-612,362.22
-4,302.44
-473,872.43
-280,660.46
-67,676.02
-4,812.21
-356.44
-125.57
-31.01
-19.61
-1.54
-0.31
-0.82
0.16
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-62.5
-13,044.88
-19,334.62
-1,184,127.44
-10,077.78
-1,312,944.43
-1,012,204.48
-335,289.93
-23,815.33
-2,729.85
-531.11
-212.93
-195.31
-91.06
-57.78
-53.11
-34.79
Book Value per Share
-4,449.38
-8,714.75
-13,857
-314,510.33
-4,998.78
417,380.5
-80,220.15
-35,532.62
618.52
-307.8
79.97
-16.36
-17.91
-5.87
-4.47
-3.7
-0.73
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
1
3
6
6
10
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
3
3
4
7
28
66
97
107
65
66
57
Sales/Revenue/Turnover
- -
-3,220.34
-2,995.09
-10,770.31
-5,748.9
-2,915.53
-554.28
-585.35
-487.53
-230.13
-64.86
-58.26
-37.35
-11.48
0.87
3.82
-12.19
Operating Margin (%)
- -
- -
- -
- -
- -
- -
1
4
3
3
6
9
10
9
7
5
4
Depreciation Expense
- -
- -
- -
-6
- -
-8
-28
-23
-10
-27
-14
-58
-109
-17
-16
-14
-34
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
-3,410
-3,275.31
-9,466.8
-6,172.3
-2,950.32
-1,099.66
-698.58
-278.35
-370.64
-49.29
-88.81
-112.53
-15.88
-24.31
-20.43
-60.17
Profit Margin (%)
- -
- -
- -
-3
- -
7
- -
-1
6
10
47
-4
-5
2
- -
16
7
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
14
15
11
11
10
LT Debt
- -
- -
- -
5
- -
16
10
4
13
7
95
138
44
39
28
19
35
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
1.18
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
ST Debt
17
11
12
LT Borrowings
10
10
10
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
10
11
11
Market Capitalization
14
22
27

Working Capital

FRC

•

in mil. unless spec.
Sep'26
Dec'26
Mar'26
Total Current Assets
81
76
67
Cash, Cash Equivalents & STI
33
30
27
Accounts Receivable, Net
33
31
24
Inventories
10
9
7
Total Current Liabilities
66
66
60
Payables & Accruals
40
46
40
ST Debt
17
11
12
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
123.79%
-19.06%
-31.57%
Free Cash Flow
26.31%
10.92%
200.82%
Net Income, GAAP
61.53%
61.75%
-14.4%
Sales/Revenue/Turnover
145.41%
31.69%
1.84%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
18
19
14
18
65
2025
17
16
18
15
66
2026
14
15
12
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-1.48
-0.04
-0.52
- -
-2.86
2025
0.24
0.13
0.65
- -
-2.16
2026
0.21
-1.05
-0.53
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
PPD, Inc. (PPD)
China Traditional Chinese Medicine Holdings Co. Limited (0570.HK)
Dali Pharmaceuticalco.,Ltd (603963.SS)
Guizhou Xinbang Pharmaceutical Co., Ltd. (002390.SZ)
Solara Active Pharma Sciences Limited (SOLARA.BO)
Poko Innovations Inc. (POKO.CN)
Business
Aytu BioPharma, Inc. (NASDAQ: AYTU) operates as a specialty pharmaceutical company focused on commercializing novel therapeutics for complex central nervous system (CNS) conditions, including major depressive disorder (MDD) and attention deficit/hyperactivity disorder (ADHD). The company markets prescription products such as Adzenys XR-ODT and Cotempla XR-ODT, extended-release orally disintegrating tablets for ADHD treatment in patients six years and older; Karbinal ER, an extended-release antihistamine suspension for pediatric allergies; and pediatric multi-vitamins Poly-Vi-Flor and Tri-Vi-Flor addressing fluoride deficiencies. It also offers Natesto, a nasal testosterone formulation for male hypogonadism, and plans to launch EXXUA (gepirone), a first-in-class selective serotonin 5HT1a receptor agonist approved for MDD in adults. Founded in 2015 and headquartered in Denver, Colorado, Aytu BioPharma conducts operations primarily in the United States with out-licensing partnerships internationally, including for ADHD products in markets like Israel and Canada. Recent developments include an exclusive U.S. commercialization agreement for EXXUA in 2025, supported by a patent term extension, a $16.6 million public offering, and an expanded lending facility with Eclipse Business Capital extending to 2029; the company divested its consumer health business and exited in-house manufacturing by mid-2024, suspended R&D pipeline development to prioritize CNS-focused profitability, and achieved consistent adjusted EBITDA of $9-10 million over the past three years with over $30 million in cash as of June 2025.

Company News

APIChatGPT

  • accessnewswire.com

    Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026

  • accessnewswire.com

    Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

  • seekingalpha.com

    Aytu BioPharma, Inc. (AYTU) Q3 2026 Earnings Call Transcript

  • zacks.com

    Aytu BioPharma, Inc. (AYTU) Reports Q3 Loss, Tops Revenue Estimates

  • accessnewswire.com

    Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results

  • accessnewswire.com

    Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026

  • defenseworld.net

    Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Consensus Recommendation of “Hold” from Analysts

  • seekingalpha.com

    Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript

  • zacks.com

    Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates

  • accessnewswire.com

    Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

  • zacks.com

    New Strong Sell Stocks for February 2nd

  • accessnewswire.com

    Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

  • defenseworld.net

    Aytu BioPharma Inc. (NASDAQ:AYTU) Given Average Recommendation of “Hold” by Brokerages

  • seekingalpha.com

    Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript

  • accessnewswire.com

    Aytu BioPharma Recaps Investor Day Held on January 20, 2026

  • accessnewswire.com

    Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

  • accessnewswire.com

    Aytu BioPharma Details Agenda for Investor Day Scheduled for January 20, 2026 in New York City

  • defenseworld.net

    Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Consensus Recommendation of “Hold” from Brokerages

  • accessnewswire.com

    Aytu BioPharma to Host Investor Day on January 20, 2026 in New York City

  • accessnewswire.com

    Aytu BioPharma Announces Commercial Availability of EXXUA(TM) (gepirone) Extended-Release Tablets, the First and Only 5HT1a Agonist Indicated for the Treatment of Major Depressive Disorder in Adults